Nexus Pharmaceuticals Receives FDA Approval for Fluorescein Injection, USP
26 Sep 2023
Drug Approval
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- Nexus Pharmaceuticals, Inc., announced it has received U.S. Food and Drug Administration (FDA) approval for Fluorescein Injection, USP.
“Receiving FDA approval for Fluorescein Injection is another exciting step made towards addressing a supply shortfall of a critical medication on the FDA drug shortage list,” said Usman Ahmed, President and Chief Executive Officer. “Nexus stands ready to continue to be part of the solution in the battle against drug shortages.”
Nexus Pharmaceuticals’ Fluorescein Injection, USP 10% is available in cartons of ten 5 mL Single-dose Vials.
About Fluorescein Injection, USP 10%
Fluorescein Injection, USP 10% is a sterile solution indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.
About Nexus Pharmaceuticals, LLC
Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.